Key Points Akebia Therapeutics is a biotech specializing in treatments for chronic kidney diseases (CKD). Its lead drug, Vafseo, received FDA approval for treating anemia in adult CKD patients who have at least 3 months of dialysis. Vafseo is an oral tablet that has been approved in 37 countries. 5 stocks we like better than Akebia Therapeutics Akebia Therapeutics Inc. NASDAQ: AKBA is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management fo ...